|
Glycominds' IBDX® serology panel enables the most accurate, reliable and cost-effective serological microbial glycan-based blood testing available for clearly characterizing disease activity in Crohn's Disease patients. IBDX quickly identifies CD patients facing a higher risk of aggressive disease behavior and possible surgery, even before the onset of symptoms.
IBDX leverages improved sensitivity and specificity based on 4 powerful microbial, glycan-based, serological biomarkers. ALCA, ACCA and AMCA, IBDX's novel sugar-antigens - working together with gASCA, Glycominds' second generation and improved mannan antigen (gASCA) - deliver superior results due to IBDX's unique sugar chemistry definitions and innovative proprietary panel of gastro markers. IBDX enables the identification of early stage IBD patients, while differentiating between CD and UC with an overall diagnostic accuracy rate of 80% and identifies CD patients at risk for more aggressive disease behavior. IBDX's serological testing is comprised of the patented and proprietary glycan markers: ALCA, ACCA, AMCA, as well as an advanced gASCA and pANCA tests.
IBDX Panel: Major Diagnostic Benefits & Features:
- Higher sensitivity: ~ 80% sensitivity, more than any other kit due to unique sugar chemistry and innovative
panel of gastro markers.
- Higher specificity: Employing gASCA in combination with ALCA, ACCA and AMCA allows 90-99% specificity
for IBD and Crohn's Disease.
- Identifies ASCA-negative Crohn's Disease patients: AMCA, ALCA & ACCA can identify 35% to 45% of
ASCA-negative CD patients.
- High positive predictive value (PPV): Over 90% PPV for IBD diagnosis when compared with other GI diseases.
Over 85% PPV for the differentiation between CD and UC.
Additional Diagnostic Benefits:
IBD differential diagnosis
Glycominds IBDX panel significantly reduces the period of elapsed time, as well as procedures needed until final diagnosis confirmation (by biopsy). The panel maintains a rate of 65% sensitivity and 85% specificity for IBD differential diagnosis.
Earlier diagnosis
The IBDX panel enables earlier diagnosis as compared to current invasive procedures. Earlier diagnosis enables more accurate treatment. Additionally important, early diagnosis of IBD can prevent complications, including colon removal in 25% to 40% of Ulcerative Colitis patients (NIH, NIDDK, 4/00).
Pediatric and Young Patients Testing
IBDX is a simple, non-invasive solution ideal for testing pediatric and young sufferers of Crohn's Disease
Crohn's disease improved diagnostics including Family Screening
IBDX panel enables to identify CD patients at higher sensitivity and specificity and even predicts CD patients before clinical symptoms. Additionally, IBDX is the ideal means of carrying out family screening for Crohn's Disease.
Non-invasive procedures
The serological tests delivered by IBDX eliminate the need for invasive procedures, easing your patients' physical and psychological state-of-being.
Quick and Easy to Use
All kits have short incubation times and ready-to-use reagents.
IBDX Major Prognostic Benefits & Features:
Implementing Glycomind's IBDX serology panel testing at any stage in the analysis of your patients' disease characterization workups, provides you with highly accurate additional information for clearer diagnosis and disease prognosis. This enhances your ability to offer patients the very best in individualized and effective treatment for their disease.
IBDX panel testing is an excellent tool for making decisions regarding IBD and CD patients:
High Risk (Relative risk and hazard ratio over 2)for more aggressive disease behavior for CD patients with two or more positive IBDX markers -
Additional Prognostic Benefits:
CD severity
The IBDX panel predicts severity and complications of CD (strictures, fistulas and the need for surgery). Additionally, the panel is an excellent aid for the selection of appropriate treatment options (i.e. - steroid reduction, the use of biological if and when required…).
Prediction value
IBDX enables to predict whether patients are CD sufferers months before clinical symptoms materialize, and can be used already at onset. Prediction of CD complications and surgery: Recent studies have demonstrated that gASCA, ACCA, AMCA may predict increased disease severity and complications of CD (strictures or fistulas) as well as with the need for surgery.
Correlation with CD genes
Recent studies correlate gASCA, ALCA and AMCA with mutations and genetic variants in innate immunity genes associate with CD.
Important Note:
IBDX, like all other serological tests, cannot diagnose all IBD patients since:
- 25% of CD and 60% of UC patients may not have serologic markers .
- CD patients with colon disease may not have high level of serological markers, even in more aggressive disease course.
|
